1 2	Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity
3	
4 5	Alberto Cagigi <sup>1</sup> , Meng Yu <sup>1</sup> , Sara Falck-Jones <sup>1</sup> , Sindhu Vangeti <sup>1</sup> , Björn Österberg <sup>1</sup> , Eric Åhlberg <sup>1</sup> , Lida Azizmohammadi <sup>1</sup> , Ryan Falck-Jones <sup>2,3</sup> , Pia C Gubisch <sup>1</sup> , Mert Ödemis <sup>1</sup> ,
6	Farangies Ghafoor <sup>1</sup> , Klara Lenart <sup>1</sup> , Max Bell <sup>2,3</sup> , Niclas Johansson <sup>4,5</sup> , Jan Albert <sup>6,7</sup> , Jörgen
7	Sälde <sup>8</sup> , Deleah Pettie <sup>9,10</sup> , Michael Murphy <sup>9,10</sup> , Lauren Carter <sup>9,10</sup> , Neil P King <sup>9,10</sup> , Sebastian Ols <sup>1</sup> ,
8	Anna Färnert <sup>4,5</sup> , Karin Loré <sup>1*</sup> and Anna Smed-Sörensen <sup>1*</sup>
9	
10	<sup>1</sup> Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
11	Karolinska University Hospital, Stockholm, Sweden. <sup>2</sup> Department of Physiology and
12	Pharmacology, Karolinska Institutet, Stockholm, Sweden. <sup>3</sup> Department of Perioperative
13	Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. <sup>4</sup> Division of
14	Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine,
15	Karolinska Institutet, Sweden. <sup>5</sup> Department of Infectious Diseases, Karolinska University
16	Hospital Solna, Stockholm, Sweden. <sup>6</sup> Department of Microbiology, Tumor and Cell Biology,
17	Karolinska Institutet, Stockholm, Sweden. <sup>7</sup> Clinical Microbiology, Karolinska University
18	Hospital Solna, Stockholm, Sweden. <sup>8</sup> Närakut SLSO, Karolinska University Hospital Solna,
19	Stockholm, Sweden. <sup>9</sup> Department of Biochemistry, University of Washington, Seattle, WA
20	98195, United States. <sup>10</sup> Institute for Protein Design, University of Washington, Seattle, WA
21	98195, United States. <sup>*</sup> Equal contribution.
22	
23	Correspondence to:
24	Karin Loré and Anna Smed-Sörensen, Division of Immunology and Allergy, Department of
25	Medicine Solna, Karolinska Institutet, Visionsgatan 4, BioClinicum J7:30, Karolinska
26	University Hospital, 171 64 Stockholm, Sweden.
27	e-mail addresses: <u>karin.lore@ki.se</u> ; <u>anna.smed.sorensen@ki.se</u>
28	
29	Conflict of interest statement
30	The authors have declared that no conflict of interest exists.
31	
32	
33	Summary
34	
35	COVID-19 severity determines the level of systemic and airway IgG and IgA but while IgG are
36	maintained in plasma during convalescence, antibodies wane rapidly in the airways.
37	However, comparable levels of antigen-specific memory B cells are generated across disease
38	severity.
39	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. No reuse allowed without permission.

#### 40 Abstract

- 41
- 42 Understanding immune responses following SARS-CoV-2 infection in relation to COVID-19
- 43 severity is critical for predicting the effects of long-term immunological memory on viral
- 44 spread. Here we longitudinally assessed systemic and airway immune responses against
- 45 SARS-CoV-2 in a well-characterized cohort of 147 infected individuals representing the full
- 46 spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. High systemic
- 47 and airway antibody responses were elicited in patients with moderate to severe disease,
- 48 and while systemic IgG levels were maintained after acute disease, airway IgG and IgA
- 49 declined significantly. In contrast, individuals with mild symptoms showed significantly lower
- 50 antibody responses but their levels of antigen-specific memory B cells were comparable with
- 51 those observed in patients with moderate to severe disease. This suggests that antibodies in
- 52 the airways may not be maintained at levels that prevent local virus entry upon re-exposure
- and therefore protection via activation of the memory B cell pool is critical.
- 54
- 55

All rights reserved. No reuse allowed without permission.

#### 56 Introduction

#### 57

58 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes 59 coronavirus disease 2019 (COVID-19) can present with a wide range of disease severity from 60 asymptomatic to fatal. Individuals of advanced age and/or those with comorbidities are 61 overrepresented among patients who develop severe disease (Zaki et al., 2020). However, the majority of SARS-CoV-2 infected individuals experience asymptomatic infection or only 62 63 mild disease (Moghadas et al., 2020). Understanding immune responses following SARS-CoV-2 infection in relation to COVID-19 severity is critical for predicting long-term immunological 64 65 memory and the potential risk for re-infection or virus spread. Whether patients with 66 different disease severities generate similar protective immunity is still unknown. Here we 67 present longitudinal data on virus-specific systemic and airway antibody and B cell memory 68 responses generated in a clinically well-characterized cohort of individuals with SARS-CoV-2 69 infection (n=147) representing the full spectrum of COVID-19 severity ranging from 70 asymptomatic infection to fatal disease.

- 71
- 72

#### 73 **Results and discussion**

- 74
- 75 Individuals were sampled during disease and convalescence with longitudinal, donor-
- 76 matched blood and airway samples. The levels of systemic and airway antibody responses as
- 77 well as the generation of SARS-CoV-2-specific memory B cells were measured. Plasma,
- 78 peripheral blood mononuclear cells (PBMC), nostril swabs (NSW) and nasopharyngeal
- 79 aspirates (NPA) were collected across all disease severities whereas endotracheal aspirates
- 80 (ETA) were collected only from intubated patients receiving intensive care (Figure 1A).
- 81 Disease severity was assessed daily, using a seven-point scale derived from the respiratory
- 82 domain of the sequential organ failure assessment (SOFA) score (Grissom et al., 2010;
- Vincent et al., 1996), with additional levels for non-admitted mild cases (1) and fatal cases 83
- 84 (7). Patients were later grouped based on peak disease severity (PDS) (Table 1). In addition,
- 85 pre-pandemic healthy controls (PPHC) (n=30) as well as individuals who experienced
- influenza-like symptoms and were possibly exposed to SARS-Cov-2 but had a negative 86 87 diagnostic PCR (PCR-) (n=9) were sampled in the same way and included as controls.

88

89 We first assessed systemic IgG and IgA responses at the time of study inclusion that ranged 90 between 0-54 days from onset of symptoms; median 16 days. Generally, patients with the

- 91 highest peak disease severity score were included in the study after they had already been 92
- hospitalized for a number of days (Figure 1B) (Falck-Jones et al., 2020). Therefore, these 93 individuals were sampled longer after symptom onset as compared with individuals with
- 94 mild disease resulting in a large time frame of study inclusion with respect to symptom onset
- 95 (Table 1). For simplicity, this sampling period/study inclusion is referred to as the "acute"
- phase. Samples collected at the first follow-up visit (46-168 days; median 108 days) are 96
- 97 referred to as the "convalescent" phase. Time of convalescent from acute sampling ranged
- 98 based on individual patient recovery and their disease severity (33-159 days; median 90
- 99 days). Plasma IgG and IgA against the SARS-CoV-2 nucleocapsid (N) and spike (S) proteins as
- 100 well as the receptor binding domain (RBD) (Walls et al., 2020; Wrapp et al., 2020) of the S
- 101 protein were measured by ELISA. Antibody responses against the internal N protein have
- 102 been shown to be elevated in deceased individuals but whether these antibodies contribute

All rights reserved. No reuse allowed without permission.

to disease severity is unknown (Atyeo et al., 2020; Guthmiller et al., 2020). In contrast,
antibody responses against the viral surface protein S and, in particular, against the RBD
result in virus neutralization (Piccoli et al., 2020). Responses against the RBD are thus likely
necessary for protection from re-infection or prevention of symptomatic disease.

106 107

108 In line with previous reports (Atyeo et al., 2020; Gaebler et al., 2020; Gudbjartsson et al., 109 2020; Guthmiller et al., 2020; Zhao et al., 2020), plasma IgG and IgA responses against N, S 110 and RBD were robust in acute disease in the majority of individuals with moderate to severe 111 disease while they were substantially lower in individuals with mild disease (Figure 2A). 112 However, in our cohort, this might also partially be due to earlier study inclusion of patients 113 with mild symptoms (median days from onset of symptoms 11 as compared with 13 and 114 21.5 in the moderate and severe groups respectively, and 13 in the fatal group) (Table 1). In 115 fact, while plasma IgG levels remained high in the patients with moderate to severe disease 116 in the convalescent phase, levels had increased in the individuals with mild disease and all 117 had seroconverted (Figure 2A). In contrast, IgA levels from the acute phase, against all 118 antigens, waned substantially during convalescence in most patients (Figure 2A). While the 119 levels of IgG against the RBD (Figure 2B), as well as against N and S (Figure S1A), exhibited a 120 positive correlation with days from onset of symptoms during the acute phase, this was less 121 pronounced for IgA levels. Furthermore, patients with mild disease displayed lower levels of 122 plasma IgG against RBD as compared with more severe patients, also when samples were 123 taken after similar duration of symptoms (Figure 2A-B and Figure S1B). Altogether, these 124 data confirm that the generation of IgA likely precede that of IgG. Earlier reports of 125 individuals with asymptomatic infection or mild disease also showed robust early IgA 126 responses (Cervia et al., 2020; Staines et al., 2020; Sterlin et al., 2020).

127

128 Comparable to another study (Hansen et al., 2020), the levels of both plasma IgG and IgA 129 against all antigens tested, during both acute disease and convalescence, were significantly 130 higher in patients with more severe disease compared to mild, both when comparing 131 disease severity at time of study inclusion and initial sampling as well as when grouping the 132 patients based on their peak disease severity (Figure S2A). When comparing antibody levels 133 between disease severity groups based on when patients were sampled after disease onset, 134 patients with moderate or severe disease on average tended to have higher antibodies 135 compared to those with mild disease already during the first week of symptom onset and 136 were more pronounced after 2, 3 and >3 weeks of symptom onset (Figure S1B). However, 137 these differences were not statistically significant in our cohort, probably due to uneven 138 inclusion over time in the different disease severity groups. In our cohort, the difference in 139 antibody titers over time was further supported by the fact that the patients with 140 moderate/severe disease, and even fatal outcome, for whom we initially observed low IgG 141 titers against RBD, had an early study inclusion (on average 13 days from onset of 142 symptoms); but showed significantly higher titers later during the acute phase (on average 143 19 days) (Figure 2C-D). Similar kinetics of anti-RBD responses have previously been noted in 144 different patient cohorts (Lynch et al., 2020; Robbiani et al., 2020; Rydyznski Moderbacher 145 et al., 2020).

146

As the respiratory tract is the initial site of viral infection and replication, we next measured
the levels of IgG and IgA in the upper and lower airways and compared with levels in plasma
at matched time points. Due to limited sample volumes, we focused our analyses on IgG and

All rights reserved. No reuse allowed without permission.

150 IgA responses against the RBD since these responses are likely most critical for virus neutralization. We found that RBD-specific antibodies could be readily detected in NSW and 151 152 NPA during the acute phase in several patients across all disease severities (Figure 3A and B). 153 In agreement with our observations in plasma, antibody levels in the upper respiratory tract 154 were higher in patients with moderate or severe disease as compared with individuals with 155 mild disease. Both IgG and IgA levels declined significantly in the convalescent phase, with 156 IgG declining to almost undetectable levels (Figure 3A and B). This demonstrates that airway 157 antibody levels wane much faster than those in plasma during convalescence. Low but 158 detectable levels of antibodies to SARS-CoV-2 have previously been reported also in saliva 159 during convalescence (Isho et al., 2020). However, whether these low antibody levels at 160 mucosal sites will be sufficient for protection is not known. We found that RBD-specific IgG 161 and IgA levels in the respiratory tract correlated well with those in plasma during the acute 162 phase but to a lesser extent during convalescence (Figure 3C and Figure S2B). When 163 comparing donor-matched NSW, NPA and ETA collected at the same time point during acute 164 disease from intubated patients, significantly higher levels of IgA against the RBD were found 165 in NPA as compared with NSW and ETA (Figure 3D). While this could be partially influenced 166 by differences in sampling method and sample volume, these data suggest that antibody abundance and possibly virus neutralization via IgA differs along the respiratory tract and 167 168 may be more pronounced in the nasopharynx compared to the lower airways. Hence, 169 nasopharynx antibodies (both IgG and IgA) showed a strong correlation with plasma 170 antibody responses (Figure 3D and Figure S2B). We also assessed the presence of B cells in 171 the respiratory tract of COVID-19 patients by analyzing the lymphocytes that could be 172 retrieved from NPA and ETA as compared with NPA from three additional healthy controls 173 (HC). Lymphocyte frequencies were lower in both NPA and ETA from several COVID-19 174 patients as compared with NPA from HC. The proportion of B cells of lymphocytes was 175 similar in NPA from HC and COVID-19 patients. However, the proportion of B cells in ETA of 176 COVID-19 patients was lower compared to NPA, which possibly contributes to the higher 177 antibody levels at this site (Figure 4A and B).

178

179 Altogether, the data presented so far confirm that moderate and severe COVID-19 result in 180 high levels of circulating antibodies and show that despite IgG being well-maintained during 181 convalescence, antibody levels in the airways decline significantly after the acute phase. 182 Generally, antibodies present in circulation and at local sites are the result of secretion from 183 short-lived plasmablasts and/or terminally differentiated plasma cells in the bone marrow or 184 mucosal sites (Zielinski et al., 2011). The response to a secondary infection once antibody 185 titers have waned below protective levels mostly relies on the presence of resting antigen-186 specific memory B cells that are rapidly activated upon antigen re-exposure (Zielinski et al., 187 2011). We therefore investigated the induction and maintenance of antigen-specific 188 memory B cells similar to other studies (Dan et al., 2020; Juno et al., 2020; Rodda et al., 189 2020). We focused on the direct comparison between individuals with mild disease and 190 patients with moderate/severe disease, along with individuals who had reported mild 191 influenza-like symptoms but were SARS-CoV-2 PCR-. Patients with moderate/severe disease 192 who had high circulating IgG and IgA levels were specifically selected for the analysis to be 193 able to compare the opposite ends of the COVID-19 disease spectrum. Donor-matched 194 PBMC from acute disease and convalescence were analyzed side-by-side using fluorescently 195 labelled S and RBD probes to detect antigen-specific B cells (Dan et al., 2020; Juno et al., 196 2020; Rodda et al., 2020). Patients with moderate/severe disease had switched memory B

All rights reserved. No reuse allowed without permission.

197 cells specific to S in the acute phase and the memory B cell pool had further expanded in the 198 convalescent phase (ranging from 0.009 to 1.35%; mean 0.42% during convalescence) 199 (Figure 4C-F). Individuals with mild disease showed lower memory B cells during acute 200 disease than the patients with moderate/severe disease, but the levels had increased by the 201 time of convalescent sampling (ranging from 0.17% to 0.64%; mean 0.35% during 202 convalescence) and were comparable between the groups (Figure 4E and F). Further 203 phenotyping of the S-specific memory B cells indicated that the majority of these cells may 204 be specific for epitopes on S outside of the RBD (Figure 4D). However, it is possible that 205 binding of B cells to RBD could be underestimated as RBD is also present in the S protein. S-206 specific memory B cells in the circulation were predominantly IgG+, rather than IgA+ (Figure 207 4D). Low frequencies of S and RBD-specific memory B cells were observed in the PCR-208 individuals. However, these were not significantly different from the levels observed in PPHC 209 (Figure 4C and E). Collectively, since the majority of individuals infected with SARS-CoV-2 are 210 either asymptomatic or experience only mild COVID-19 symptoms (Moghadas et al., 2020), 211 the possibility of generating antigen-specific memory B cells without experiencing severe 212 disease, would be very important in the prospect of establishing potential immunity at the 213 population level.

214

215 In summary, here we show that COVID-19 disease severity not only determines the

216 magnitude of systemic but also airway antibody levels with efficient generation of virus-

217 specific memory B cells against SARS-CoV-2 also occurring upon mild disease. While plasma

- 218 IgG levels were generally well detectable at convalescence in all groups, there was a
- significant decline in airway antibodies after the clearance of infection. This suggests that
- 220 antibodies in the airways may not be maintained at levels that prevent local virus entry upon
- re-exposure. However, our data indicate that the majority of infected individuals have the
- ability to generate anamnestic responses via the memory B cell pool. Speculatively, the
- antibodies and memory B cell pool may play a role for protection or mitigation of disease
- severity in case of re-infection. Whether sufficient number of memory B cells will be
- maintained long-term and to what extent they will prevent the spread of SARS-CoV-2 at the
- 226 population level remain to be understood. This is critical knowledge to acquire in the near
- future to evaluate together with the memory B cell response generated after the
   introduction of SARS-CoV-2 vaccination. Ultimately, the requirements for establishment of
- 229 long-term protection and immunity will need to be determined.
- 230
- 231

# 232 Materials and methods

233

# 234 Study design, patient enrollment and sample collection

235 One hundred and forty-seven (147) PCR-confirmed SARS-CoV-2 infected patients were 236 enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut), 237 Stockholm, Sweden during March-May 2020 (acute phase) in a time that ranged from 0 to 238 54 days from onset of symptoms as self-reported by individual patients; and during April-239 September 2020 (convalescence) in a time that ranged from 46 to 168 days continuing from 240 the previous counts. Patients were enrolled at various settings, ranging from primary to 241 intensive care. In order to recruit asymptomatic and mild cases, household contacts of 242 COVID-19 patients were screened with PCR and enrolled if positive. A small subset of these 243 individuals who experienced influenza-like symptoms and were possibly exposed to SARS-

All rights reserved. No reuse allowed without permission.

Cov-2 but had a negative diagnostic PCR (PCR-) (n=9 of whom 3 were household contacts of
confirmed patients with 1 experiencing fever, and 6 were included based on suspected
infection with 4 experiencing fever) were sampled in the same way and included as controls

alongside with 30 pre-pandemic healthy control samples (PPHC) from 2016-2018.

248

249 Respiratory failure was categorized daily according to the respiratory domain of the 250 Sequential Organ Failure Assessment score (SOFA) (Vincent et al., 1996). The modified SOFA 251 score (mSOFA) was calculated when arterial partial pressure of oxygen  $(PaO_2)$  was not 252 available. In this case peripheral transcutaneous hemoglobin saturation (SpO<sub>2</sub>) was used 253 instead (Grissom et al., 2010). Estimation of the fraction of inspired oxygen (FiO<sub>2</sub>) based on 254 O<sub>2</sub> flow was calculated as per the Swedish Intensive Care register definition 255 (Intensivvårdsregistret, 2018). Patients were categorized based on the peak respiratory 256 SOFA or mSOFA value with the 5-point respiratory SOFA score being extended with 257 additional levels to include and distinguish admitted asymptomatic and non-258 admitted/admitted mild cases and to include fatal outcome added as a seventh level. Ten 259 (10) patients with fatal outcome had peak disease severity score 6 prior to death and 2

- 260 patients had scores of 4 and 5. For convenience, the resulting 7-point composite peak
- disease severity (PDS) was condensed into a broader classification consisting of mild (1-2),
- 262 moderate (3-4), severe (5-6), and fatal (7). Demographics and additional data were collected
- from medical records, including clinical history and risk factors such as BMI and co-
- 264 morbidities. Total burden of comorbidities was assessed using the Charlson co-morbidity
   265 index (CCI) (Charlson et al., 1987) (Table 1). Additional clinical information on this patient
- cohort including the modulation of disease from time to study inclusion to peak severity can
  be found in Falck-Jones et al (Falck-Jones et al., 2020).
- 268

269 Blood was collected in EDTA-containing tubes from all patients except those admitted to the 270 intensive care unit (ICU) for whom blood was pooled from heparin-coated blood gas syringes 271 discarded in the last 12 hours. For some ICU patients, additional venous blood was also 272 collected in EDTA tubes. Nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were 273 collected from the majority of the patients whereas endotracheal aspirates (ETA) were only 274 collected from patients with mechanical ventilation intubated in the ICU. Admitted patients 275 were sampled during acute disease at up to four timepoints and ICU patient material was 276 collected up at to ten timepoints. For this study, unless otherwise stated, the measurements 277 referring to acute disease were performed with samples collected at the time of study 278 inclusion and during convalescence when patients returned for a follow-up visit.

279

The study was approved by the Swedish Ethical Review Authority, and performed according to the Declaration of Helsinki. Written informed consent was obtained from all patients and controls. For sedated patients, the denoted primary contact was contacted and asked about the presumed will of the patient and to give initial oral and subsequently signed written consent. When applicable retrospective written consent was obtained from patients with non-fatal outcomes.

286

# 287 Enzyme-linked immunosorbent assay (ELISA)

288 The presence of IgG or IgA binding against the SARS-Cov-2 Nucleocapsid (N) and Spike (S)

- trimer or the Receptor Binding Domain (RBD) monomer (Walls et al., 2020) in plasma and
- airway samples was assessed by enzyme-linked immunosorbent assay (ELISA). Recombinant

All rights reserved. No reuse allowed without permission.

291 proteins were received through the global health-vaccine accelerator platforms (GH-VAP) 292 funded by the Bill & Melinda Gates Foundation. Briefly, 96-half well plates were coated with 293 50ng/well of the respective protein. Plates were incubated with a selected duplicate dilution 294 that did not provide background noise against ovalbumin used as a negative control (data 295 not shown) (i.e. 1:20 for plasma samples, 1:2 for NSW and NPA, and 1:5 for ETA in 5% 296 milk/PBS buffer). Duplicate 7-point serial dilutions were initially performed for measuring 297 plasma IgG against RBD during acute disease and the half maximal effective concentration 298 (EC<sub>50</sub>) was calculated using GraphPad Prism 9. However, since for several samples with low 299 antibody concentration (mostly from the asymptomatic/mild category) the EC<sub>50</sub> was below the highest dilution used (of 1:20) and therefore below the limit of detection (Figure S3A), 300 301 the maximal optical density (OD) at 1:20 dilution was used instead for this and for all the 302 other measurements subsequently performed. The relation with maximal OD and EC<sub>50</sub> was 303 also verified in a subset of patients with high IgG and IgA against S (Figure S3B). Detection 304 was performed with mouse and goat anti-human IgG or IgA HRP-conjugated secondary 305 antibodies (clone G18-145 from BD Biosciences and polyclonal from ThermoFisher, 306 respectively) followed by incubation with TMB substrate (BioLegend) which was stopped 307 with a 1M solution of sulfuric acid. Blocking with 5% milk/PBS buffer and washing with 0.1% 308 Tween-20/PBS buffer were performed between each step. Absorbance was read at 450nm 309 and background correction at 550nm using an ELISA reader. Data were reported as maximal 310 absorbance i.e. OD, as stated above, and plotted using GraphPad Prism 9. All of the antibody 311 measurements in plasma and respiratory samples from SARS-CoV-2 patients were run 312 alongside with samples from two different control groups as described above. Interestingly, 313 low but readily detectable IgA reactivity against S was detected in the pre-pandemic healthy 314 controls and in the PCR- individuals (Figure S3C). After having verified the specificity and 315 sensitivity of our ELISA assay for IgA detection with limiting sample dilutions (Figure S3D), we 316 hypothesize that this might be due to cross-reactivity on the shared portions of the S protein 317 between SARS-CoV-2 and other common cold coronaviruses. Reports have shown that cross-318 reactivity between coronaviruses exists (Grifoni et al., 2020; Song et al., 2020).

319

#### 320 Flow cytometry

321 Staining of cells from airway samples was performed fresh. Briefly, samples were centrifuged 322 at 400 g for 5 min at room temperature and cells were washed with sterile PBS. Mucus was 323 removed using a 70 µm cell strainer and cells were subsequently stained with the 324 appropriate combination of fluorescently labelled monoclonal antibodies as illustrated in 325 Figure 4A. Staining of PBMC was performed on previously cryopreserved samples. The 326 appropriate combination of fluorescently labelled monoclonal antibodies binding to 327 different cell surface markers and with fluorescently labelled S and RBD proteins used as 328 probes for antigen-specific B cells is illustrated in Figure 4C. Probes were prepared from 329 biotinylated proteins using a 4:1 molar ratio (protein:fluorochrome-labelled streptavidin) 330 considering the molecular weight of protein monomers and of the streptavidin only. The probes were prepared using streptavidin conjugated to PE and APC for S and with BV421 for 331 332 the RBD. The gating strategy for the identification of antigen-specific memory B cells is 333 shown in Figure 2d. Briefly, after identification of lymphocytes in single suspension, live B 334 cells, (i.e. cells not expressing CD3/,CD14/CD16/CD56) were gated. From this gate, B cells 335 were further isolated by expression of CD19 and CD20 and then switched memory B cells 336 were identified as IgD-IgM-. From these, S-specific switched memory B cells were identified 337 by binding to both S protein probes. Further characterization was then carried out by

All rights reserved. No reuse allowed without permission.

- analyzing IgG expression (IgA+ switched memory B cells are assumed to mirror IgD-IgM-IgG-
- B cells) and fluorescently labelled RBD. Stained cells from airway samples were acquired
  using a BD LSRFortessa while stained PBMC were acquired using a BD FACSAria Fusion both
- interfaced with the BD FACSDiva Software. Results were analyzed using BD FlowJo version
- 342 10.
- 343

### 344 Statistical analyses

- 345 All statistical analyses were performed using GraphPad Prism 9. Spearman correlation was
- 346 used to assess the interdependence of 2 different non-categorical parameters across
- 347 individuals whereas Wilcoxon matched-pairs signed rank or Mann–Whitney U tests as
- 348 appropriate, were used to assess differences or similarities for one single parameter
- between 2 different groups. Kruskal -Wallis with Dunn's multiple comparisons test was usedwhen assessing comparison between multiple groups.
- 351
- 352

# 353 Author contributions

Experimental study design: A.C., Ka.L. and A.S-S. Clinical concept design: A.S-S., M.B., N.J.,
J.A., J.S. and A.F. Acquisition and sample processing: M.Y., S. F-J., S.V., B.Ö., E.Å., L.A., R.F-J.,
M.Ö. and F.G. Generation of data: A.C., M.Y., S. F-J., S.V. and P.C.G. Provision of custom
reagents: D.P., M.M., L.C., and N.P.K. Analysis and interpretation of data: A.C., Ka.L. and A.SS. Critical revision of the manuscript: all authors. Statistical analysis: A.C., K.L. and S.O. Ka.L.
and A.S-S. contributed equally to the study.

- 360
- 361

# 362 Acknowledgments

We thank the patients and healthy volunteers who have contributed to this study. We would also like to thank medical students and hospital staff for assistance with patient sampling and collection of clinical data, the Biomedicum BSL3 core facility, Karolinska Institutet and Fredrika Hellgren for assistance with English editing. This work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska

- 369 Institutet.
- 370
- 371

All rights reserved. No reuse allowed without permission.

#### 372 References

- Atyeo, C., S. Fischinger, T. Zohar, M.D. Slein, J. Burke, C. Loos, D.J. McCulloch, K.L. Newman,
  C. Wolf, J. Yu, K. Shuey, J. Feldman, B.M. Hauser, T. Caradonna, A.G. Schmidt, T.J.
  Suscovich, C. Linde, Y. Cai, D. Barouch, E.T. Ryan, R.C. Charles, D. Lauffenburger, H.
  Chu, and G. Alter. 2020. Distinct Early Serological Signatures Track with SARS-CoV-2
  Survival. *Immunity* 53:524-532 e524.
- Cervia, C., J. Nilsson, Y. Zurbuchen, A. Valaperti, J. Schreiner, A. Wolfensberger, M.E. Raeber,
  S. Adamo, M. Emmenegger, S. Hasler, P.P. Bosshard, E.D. Cecco, E. Bächli, A. Rudiger,
  M. Stüssi-Helbling, L.C. Huber, A.S. Zinkernagel, D.J. Schaer, A. Aguzzi, U. Held, E.
  Probst-Müller, S.K. Rampini, and O. Boyman. 2020. Systemic and mucosal antibody
  secretion specific to SARS-CoV-2 during mild versus severe COVID-19. *bioRxiv*2020.2005.2021.108308.
- Charlson, M.E., P. Pompei, K.L. Ales, and C.R. MacKenzie. 1987. A new method of classifying
   prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40:373-383.
- Dan, J.M., J. Mateus, Y. Kato, K.M. Hastie, C.E. Faliti, S.I. Ramirez, A. Frazier, E.D. Yu, A.
  Grifoni, S.A. Rawlings, B. Peters, F. Krammer, V. Simon, E.O. Saphire, D.M. Smith, D.
  Weiskopf, A. Sette, and S. Crotty. 2020. Immunological memory to SARS-CoV-2
  assessed for greater than six months after infection. *bioRxiv* 2020.2011.2015.383323.
- Falck-Jones, S., S. Vangeti, M. Yu, R. Falck-Jones, A. Cagigi, I. Badolati, B. Osterberg, M.J.
  Lautenbach, E. Ahlberg, A. Lin, I. Szurgot, K. Lenart, F. Hellgren, J. Salde, J. Albert, N.
  Johansson, M. Bell, K. Lore, A. Farnert, and A. Smed-Sorensen. 2020. Functional
  myeloid-derived suppressor cells expand in blood but not airways of COVID-19
  patients and predict disease severity. *medRxiv*
- Gaebler, C., Z. Wang, J.C.C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, M. Ladinsky, A.
  Cho, M. Jankovic, D. Schaefer-Babajew, T.Y. Oliveira, M. Cipolla, C. Viant, C.O. Barnes,
  A. Hurley, M. Turroja, K. Gordon, K.G. Millard, V. Ramos, F. Schmidt, Y. Weisblum, D.
  Jha, M. Tankelevich, J. Yee, I. Shimeliovich, D.F. Robbiani, Z. Zhao, A. Gazumyan, T.
  Hatziioannou, P.J. Bjorkman, S. Mehandru, P.D. Bieniasz, M. Caskey, and M.C.
  Nussenzweig. 2020. Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv*
- Grifoni, A., D. Weiskopf, S.I. Ramirez, J. Mateus, J.M. Dan, C.R. Moderbacher, S.A. Rawlings,
  A. Sutherland, L. Premkumar, R.S. Jadi, D. Marrama, A.M. de Silva, A. Frazier, A.F.
  Carlin, J.A. Greenbaum, B. Peters, F. Krammer, D.M. Smith, S. Crotty, and A. Sette.
  2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID19 Disease and Unexposed Individuals. *Cell* 181:1489-1501 e1415.
- 408 Grissom, C.K., S.M. Brown, K.G. Kuttler, J.P. Boltax, J. Jones, A.R. Jephson, and J.F. Orme, Jr.
  409 2010. A modified sequential organ failure assessment score for critical care triage.
  410 *Disaster Med Public Health Prep* 4:277-284.
- Gudbjartsson, D.F., G.L. Norddahl, P. Melsted, K. Gunnarsdottir, H. Holm, E. Eythorsson, A.O.
  Arnthorsson, D. Helgason, K. Bjarnadottir, R.F. Ingvarsson, B. Thorsteinsdottir, S.
  Kristjansdottir, K. Birgisdottir, A.M. Kristinsdottir, M.I. Sigurdsson, G.A. Arnadottir,
  E.V. Ivarsdottir, M. Andresdottir, F. Jonsson, A.B. Agustsdottir, J. Berglund, B.
  Eiriksdottir, R. Fridriksdottir, E.E. Gardarsdottir, M. Gottfredsson, O.S. Gretarsdottir,
  S. Gudmundsdottir, K.R. Gudmundsson, T.R. Gunnarsdottir, A. Gylfason, A. Helgason,
- 417 B.O. Jensson, A. Jonasdottir, H. Jonsson, T. Kristjansson, K.G. Kristinsson, D.N.
- 418 Magnusdottir, O.T. Magnusson, L.B. Olafsdottir, S. Rognvaldsson, L. le Roux, G.

All rights	reserved. No reus	se allowed withou	it permission.

419	Sigmundsdottir, A. Sigurdsson, G. Sveinbjornsson, K.E. Sveinsdottir, M. Sveinsdottir,
420	E.A. Thorarensen, B. Thorbjornsson, M. Thordardottir, J. Saemundsdottir, S.H.
421	Kristjansson, K.S. Josefsdottir, G. Masson, G. Georgsson, M. Kristjansson, A. Moller, R.
422	Palsson, T. Gudnason, U. Thorsteinsdottir, I. Jonsdottir, P. Sulem, and K. Stefansson.
423	2020. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 383:1724-
424	1734.

- Guthmiller, J.J., O. Stovicek, J. Wang, S. Changrob, L. Li, P. Halfmann, N.Y. Zheng, H. Utset,
  C.T. Stamper, H.L. Dugan, W.D. Miller, M. Huang, Y.N. Dai, C.A. Nelson, P.D. Hall, M.
  Jansen, K. Shanmugarajah, J.S. Donington, F. Krammer, D. Fremont, A. Joachimiak, Y.
  Kawaoka, V. Tesic, M.L. Madariaga, and P.C. Wilson. 2020. SARS-CoV-2 infection
  severity is linked to superior humoral immunity against the spike. *bioRxiv*
- Hansen, C.B., I. Jarlhelt, L. Perez-Alos, L. Hummelshoj Landsy, M. Loftager, A. Rosbjerg, C.
  Helgstrand, J.R. Bjelke, T. Egebjerg, J.G. Jardine, C. Svaerke Jorgensen, K. Iversen, R.
  Bayarri-Olmos, P. Garred, and M.O. Skjoedt. 2020. SARS-CoV-2 Antibody Responses
  Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. *J Immunol*
- 434 Intensivvårdsregistret, S. 2018. SIR:s riktlinje för registrering av SOFA. . In.
- Isho, B., K.T. Abe, M. Zuo, A.J. Jamal, B. Rathod, J.H. Wang, Z. Li, G. Chao, O.L. Rojas, Y.M.
  Bang, A. Pu, N. Christie-Holmes, C. Gervais, D. Ceccarelli, P. Samavarchi-Tehrani, F.
  Guvenc, P. Budylowski, A. Li, A. Paterson, F.Y. Yue, L.M. Marin, L. Caldwell, J.L. Wrana,
  K. Colwill, F. Sicheri, S. Mubareka, S.D. Gray-Owen, S.J. Drews, W.L. Siqueira, M.
  Barrios-Rodiles, M. Ostrowski, J.M. Rini, Y. Durocher, A.J. McGeer, J.L. Gommerman,
  and A.C. Gingras. 2020. Persistence of serum and saliva antibody responses to SARSCoV-2 spike antigens in COVID-19 patients. *Sci Immunol* 5:
- Juno, J.A., H.X. Tan, W.S. Lee, A. Reynaldi, H.G. Kelly, K. Wragg, R. Esterbauer, H.E. Kent, C.J.
  Batten, F.L. Mordant, N.A. Gherardin, P. Pymm, M.H. Dietrich, N.E. Scott, W.H. Tham,
  D.I. Godfrey, K. Subbarao, M.P. Davenport, S.J. Kent, and A.K. Wheatley. 2020.
  Humoral and circulating follicular helper T cell responses in recovered patients with
  COVID-19. *Nat Med*
- Lynch, K.L., J.D. Whitman, N.P. Lacanienta, E.W. Beckerdite, S.A. Kastner, B.R. Shy, G.M.
  Goldgof, A.G. Levine, S.P. Bapat, S.L. Stramer, J.H. Esensten, A.W. Hightower, C. Bern,
  and A.H.B. Wu. 2020. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses
  and their relationship to disease severity. *Clin Infect Dis*
- Moghadas, S.M., M.C. Fitzpatrick, P. Sah, A. Pandey, A. Shoukat, B.H. Singer, and A.P.
  Galvani. 2020. The implications of silent transmission for the control of COVID-19
  outbreaks. *Proc Natl Acad Sci U S A*
- 454 Piccoli, L., Y.J. Park, M.A. Tortorici, N. Czudnochowski, A.C. Walls, M. Beltramello, C. Silacci-455 Fregni, D. Pinto, L.E. Rosen, J.E. Bowen, O.J. Acton, S. Jaconi, B. Guarino, A. Minola, F. 456 Zatta, N. Sprugasci, J. Bassi, A. Peter, A. De Marco, J.C. Nix, F. Mele, S. Jovic, B.F. 457 Rodriguez, S.V. Gupta, F. Jin, G. Piumatti, G. Lo Presti, A.F. Pellanda, M. Biggiogero, 458 M. Tarkowski, M.S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithey, D. Hong, 459 V. Lepori, E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva, 460 G. Snell, F. Sallusto, K. Fink, H.W. Virgin, A. Lanzavecchia, D. Corti, and D. Veesler. 461 2020. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike 462 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 463 Robbiani, D.F., C. Gaebler, F. Muecksch, J.C.C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C.O.
- Barnes, A. Gazumyan, S. Finkin, T. Hagglof, T.Y. Oliveira, C. Viant, A. Hurley, H.H.
  Hoffmann, K.G. Millard, R.G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S.T. Chen, V.

466 Ramos, R. Patel, J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweger, L. Nogueira, M. 467 Pack, J. Horowitz, F. Schmidt, Y. Weisblum, E. Michailidis, A.W. Ashbrook, E. Waltari, 468 J.E. Pak, K.E. Huey-Tubman, N. Koranda, P.R. Hoffman, A.P. West, Jr., C.M. Rice, T. 469 Hatziioannou, P.J. Bjorkman, P.D. Bieniasz, M. Caskey, and M.C. Nussenzweig. 2020. 470 Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 471 Rodda, L.B., J. Netland, L. Shehata, K.B. Pruner, P.M. Morawski, C. Thouvenel, K.K. Takehara, 472 J. Eggenberger, E.A. Hemann, H.R. Waterman, M.L. Fahning, Y. Chen, J. Rathe, C. 473 Stokes, S. Wrenn, B. Fiala, L.P. Carter, J.A. Hamerman, N.P. King, M. Gale, D.J. 474 Campbell, D. Rawlings, and M. Pepper. 2020. Functional SARS-CoV-2-specific immune 475 memory persists after mild COVID-19. medRxiv 476 Rydyznski Moderbacher, C., S.I. Ramirez, J.M. Dan, A. Grifoni, K.M. Hastie, D. Weiskopf, S. 477 Belanger, R.K. Abbott, C. Kim, J. Choi, Y. Kato, E.G. Crotty, C. Kim, S.A. Rawlings, J. 478 Mateus, L.P.V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, 479 D.M. Smith, A. Sette, and S. Crotty. 2020. Antigen-Specific Adaptive Immunity to 480 SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 481 Song, G., W.T. He, S. Callaghan, F. Anzanello, D. Huang, J. Ricketts, J.L. Torres, N. Beutler, L. 482 Peng, S. Vargas, J. Cassell, M. Parren, L. Yang, C. Ignacio, D.M. Smith, J.E. Voss, D. 483 Nemazee, A.B. Ward, T. Rogers, D.R. Burton, and R. Andrabi. 2020. Cross-reactive 484 serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic 485 coronavirus infection. bioRxiv 486 Staines, H.M., D.E. Kirwan, D.J. Clark, E.R. Adams, Y. Augustin, R.L. Byrne, M. Cocozza, A.I. 487 Cubas-Atienza, L.E. Cuevas, M. Cusinato, B.M.O. Davies, M. Davis, P. Davis, A. Duvoix, 488 N.M. Eckersley, D. Forton, A. Fraser, G. Garrod, L. Hadcocks, Q. Hu, M. Johnson, G.A. 489 Kay, K. Klekotko, Z. Lewis, J. Mensah-Kane, S. Menzies, I. Monahan, C. Moore, G. 490 Nebe-von-Caron, S.I. Owen, C. Sainter, A.A. Sall, J. Schouten, C. Williams, J. Wilkins, K. 491 Woolston, J.R.A. Fitchett, S. Krishna, and T. Planche. 2020. Dynamics of IgG 492 seroconversion and pathophysiology of COVID-19 infections. medRxiv 493 Sterlin, D., A. Mathian, M. Miyara, A. Mohr, F. Anna, L. Claer, P. Quentric, J. Fadlallah, P. 494 Ghillani, C. Gunn, R. Hockett, S. Mudumba, A. Guihot, C.-E. Luyt, J. Mayaux, A. 495 Beurton, S. Fourati, J.-M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. 496 Amoura, and G. Gorochov. 2020. IgA dominates the early neutralizing antibody 497 response to SARS-CoV-2. medRxiv 498 Vincent, J.L., R. Moreno, J. Takala, S. Willatts, A. De Mendonça, H. Bruining, C.K. Reinhart, 499 P.M. Suter, and L.G. Thijs. 1996. The SOFA (Sepsis-related Organ Failure Assessment) 500 score to describe organ dysfunction/failure. On behalf of the Working Group on 501 Sepsis-Related Problems of the European Society of Intensive Care Medicine. 502 Intensive Care Med 22:707-710. 503 Walls, A.C., Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, and D. Veesler. 2020. Structure, 504 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181:281-292 505 e286. 506 Wrapp, D., N. Wang, K.S. Corbett, J.A. Goldsmith, C.L. Hsieh, O. Abiona, B.S. Graham, and J.S. 507 McLellan. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion 508 conformation. Science 367:1260-1263. 509 Zaki, N., H. Alashwal, and S. Ibrahim. 2020. Association of hypertension, diabetes, stroke, 510 cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and 511 fatality: A systematic review. Diabetes Metab Syndr 14:1133-1142.

All rights reserved. No reuse allowed without permission.

Zhao, J., Q. Yuan, H. Wang, W. Liu, X. Liao, Y. Su, X. Wang, J. Yuan, T. Li, J. Li, S. Qian, C. Hong,
F. Wang, Y. Liu, Z. Wang, Q. He, Z. Li, B. He, T. Zhang, Y. Fu, S. Ge, L. Liu, J. Zhang, N.
Xia, and Z. Zhang. 2020. Antibody Responses to SARS-CoV-2 in Patients With Novel
Coronavirus Disease 2019. *Clin Infect Dis* 71:2027-2034.

- Zielinski, C.E., D. Corti, F. Mele, D. Pinto, A. Lanzavecchia, and F. Sallusto. 2011. Dissecting
   the human immunologic memory for pathogens. *Immunol Rev* 240:40-51.
- 518
- 519

### 520 Figure legends

521

522 Figure 1. Study and sampling overview. A) Overview of study cohort and controls, timeline 523 of longitudinal sampling, the anatomical compartments analyzed, and the measurements 524 performed. AS=asymptomatic. (B) Patient sampling overview with first study sample (color) 525 and first convalescent sample (open) indicated for each patient, hospital 526 admission/discharge, level of care and outcome. Patients are group based on peak disease 527 severity (PDS); mild (PDS 1 and 2), moderate (PDS 3 and 4), severe (PDS 5 and 6) and fatal 528 (PDS 7). Individual inclusion sample for each patient is color-coded based on disease severity at the time of sampling. 529

530

531 Figure 2. Plasma IgG and IgA responses to N, S and RBD across COVID-19 severity during 532 acute disease and convalescence. A) Individual levels of plasma IgG and IgA (from left to 533 right) in SARS-CoV-2 infected individuals with different peak disease severity (PDS). Data in 534 cyan and green refer to mild disease (PDS 1 and 2), yellow and orange refer to moderate 535 disease (PDS 3 and 4), red and cayenne refer to severe disease (PDS 5 and 6) and grey refers 536 to patients with fatal outcome (PDS 7). Black lines indicate medians and dotted lines indicate 537 the average background level from pre-pandemic healthy controls. Mann-Whitney U was 538 used to compare the groups and considered statistically significant at p<0.05. \*\* p<0.01, \*\*\* 539 p<0.001, \*\*\*\* p<0.0001. B) Spearman correlation for plasma IgG (top) and IgA (bottom) 540 against the RBD versus days from onset of symptoms during the acute and the convalescent 541 phases are shown. Circles with black lining refer to convalescent samples. C-D) Longitudinal 542 measurements of plasma IgG against RBD on a subset of patients with moderate/severe 543 disease and fatal outcome who had low (< 1.0 OD) antibody titers at the time of study 544 inclusion and were longitudinal samples from symptomatic (acute) disease were available. 545 Levels are shown at the time of study inclusion, during the late acute phase and at 546 convalescence, and shown with respect to days from onset of symptoms and as a group 547 comparison. The black lines connect data points from the same individuals. Wilcoxon test 548 was used to compare the groups separately and considered statistically significant at p<0.05. 549 \*\*\*\* p<0.0001. 550

551 **Figure 3.** Airway IgG and IgA responses to RBD across COVID-19 severity during acute 552 **disease and convalescence.** A) Levels of IgG and IgA to RBD in nostrils swabs (NSW) and

nasopharyngeal aspirates (NPA). The black lines indicate median values. Mann-Whitney U
was used to compare the group and considered statistically significant at p<0.05. \*p<0.05 \*\*</li>
p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001. B) Heat map generated grouping patients according to</li>
PDS showing acute and convalescent IgG and IgA titers against N, S and RBD (plasma) and
RBC (NSW, NPA and ETA) for each patient. The heat map also includes data from PPHC and

558 PCR-individuals (indicated with PDS 0). Missing data and not available samples are shown in

All rights reserved. No reuse allowed without permission.

- black. **C)** Spearman correlation for NPA versus plasma immunoglobulins against the RBD
- 560 during acute disease. In A) the line overlaps with not detected (ND) for IgG levels. D)
- 561 Comparison of the levels of RBD IgG/A in patient-matched NSW, NPA, endotracheal
- aspirates (ETA) and plasma collected at the same time point. The black lines connect data
- points from the same individuals. Wilcoxon test was used to compare the groups separately
- and considered statistically significant at p<0.05. \*\*\*\* p<0.0001.
- 565
- 566 Figure 4. Assessment of frequencies of B cells in the respiratory tract and of circulating S-
- 567 specific memory B cells. A) Representative example with gating strategy for the
- identification of lymphocytes (identified as negative for CD14/16/123/66) and of total B cells
- 569 (CD3-CD19+) in respiratory NPA and ETA samples. **B)** Levels of lymphocytes and of total B
- 570 cells in NPA and ETA in a subset of patients alongside with NPA from healthy controls. Mann-
- 571 Whitney test was used to compare the groups and considered statistically significant at 572 p<0.05. \*\* p<0.01.
- 573 **C)** Representative examples with gating strategy of SARS-Cov-2 S-specific memory B cells
- 574 from one pre-pandemic healthy control, convalescent samples from one SARS-CoV-2 PCR-
- 575 individual and one mild and one moderate/severe COVID-19 patient. Further
- 576 characterization of S-positive memory B cells on RBD binding and B cell isotype (IgG+ or IgA+
- assumed to correspond to IgD-IgM-IgG- B cells). **D)** Pie charts show the cumulative
- 578 proportion of RBD binding and memory B cell isotypes in convalescent samples from mild
- 579 (n=6) and moderate/severe (n=8) COVID-19 patients. E) Frequencies of S-specific memory B
- 580 cells in matched acute (filled) and convalescent (filled with black lining) PBMCs in relation to
- 581 days in the subset of individuals analyzed color-coded according to PDS. Dotted lines on
- 582 indicate the average background staining from PCR- and PPHC. F) Levels of circulating Spike+
- 583 switched memory B cells during acute disease and convalesce in the subset of patients
- analyzed, as well as PPHC, color-coded according to PDS. Circles with black lining refer to
- 585 data during the convalescent phase. Black triangles symbolize the PPHC. Differences were
- 586assessed using Kruskal -Wallis with Dunn's multiple comparisons test and considered
- 587 statistically significant at p<0.05. \*\* p<0.01.
- 588
- 589 **Table 1.** Clinical characterization of the SARS-CoV-2 infected cohort.
- 590

# Α









#### **Table 1.** Clinical characterization of the SARS-CoV-2 infected cohort.

Disease severity	Mild		Moderate		Severe		Fatal
PDS	1	2	3	4	5*	6*	7
Resp. SOFA score	0	0	1	2	3	4	
Admitted (Y/N)	N	Y	Y	Y	Y	Y	Y
PFI (kPa)	> 53	> 53	< 53	< 40	< 27	< 13	-
SFI	> 400	> 400	≤ 400	≤ 315	≤ 235	< 150	
Number of individuals	13	6	10	48	19	39	12
(%)	(8.8)	(4.1)	(6.8)	(33)	(13)	(27)	(8.2)
Age, mean	44	60	56	55	57	61	66
(Range)	(24-72)	(41-72)	(46-78)	(24-76)	(42-74)	(25-77)	(52-78)
Male	5	2	6	38	15	34	9
(%)	(38)	(33)	(60)	(79)	(79)	(87)	(75)
Days from symptoms	-	10	8.5	10	7	10	7
to admission – median		(0-14)	(4-14)	(3-21)	(2-14)	(2-35)	(1-28)
(Range)							
Days from symptoms	9	11	13.5	13	21	22	13
to inclusion "Acute" –	(3-44)	(0-20)	(6-18)	(4-32)	(5-40)	(7-54)	(8-44)
median (Range)							
Days from symptoms	102	99,5	112	109	109	120	-
to follow-up "Conv" –	(88-	(82-	(81-	(46-	(48-	(53-	
median (Range)	136)	103)	127)	155)	130)	168)	
VL (Ct value) median	27.5	25.0	26.7	26.8	25.8	24.0	20.5
(Range)	(40-14)	(29-14)	(36-15)	(36-12)	(36-19)	(37-14)	(32-13)
CCI, mean	1	2	1	2	2	2	3
(SD)	(2)	(1)	(1)	(2)	(1)	(1)	(1)
BMI, mean	24.1	25.1	26.0	30.3	29.2	28.6	28.6
(SD)	(4.5)	(2.2)	(3.2)	(4.2)	(5.3)	(4.7)	(2.4)
Hypertension	1	0	2	20	8	15	9
(%)	(8.3)	(0)	(20)	(42)	(42)	(38)	(75)
Diabetes	2	0	1	14	5	9	3
(%)	(17)	(0)	(10)	(29)	(26)	(23)	(25)
Current smokers	0	0	2	5	1	2	0
(%)	(0)	(0)	(20)	(11)	(5.3)	(5.3)	(0)
ACE-I	0	0	0	5		4	
(%)	(0)	(0)	(0)	(10)	(5.3)	(10)	(9.1)
IS drugs	1			4	2	5	
(%)	(7.7)	(0)	(0)	(8.3)	(11)	(13)	(8.3)

PDS: Peak Disease Severity SOFA: Sequential Organ Failure Assessment PFI: PaO<sub>2</sub>/FiO<sub>2</sub>-index SFI: SpO<sub>2</sub>/FiO<sub>2</sub>-index VL: Viral Load CCI: Charlson comorbidity index BMI: body mass index ACE-I: angiotensin converting enzyme-inhibitors IS: immunosuppressive \*Requires mechanical ventilation